Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM)
- Conditions
- Lymphangioleiomyomatosis (LAM)Tuberous Sclerosis Complex (TSC)
- Interventions
- First Posted Date
- 2008-11-13
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 118
- Registration Number
- NCT00790400
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Minnesota Epilepsy Group, St. Paul, Minnesota, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer
- Conditions
- HER-2 Positive Breast CancerMetastatic Breast Cancer
- Interventions
- First Posted Date
- 2008-11-11
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 15
- Registration Number
- NCT00788931
- Locations
- 🇳🇱
Novartis Investigative Site, Amsterdam, Netherlands
An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA)
- Conditions
- Cystic FibrosisAllergic Bronchopulmonary Aspergillosis
- Interventions
- First Posted Date
- 2008-11-10
- Last Posted Date
- 2011-09-26
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 14
- Registration Number
- NCT00787917
- Locations
- 🇬🇧
Novartis Investigator Site, London, United Kingdom
Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
- First Posted Date
- 2008-11-06
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 89
- Registration Number
- NCT00786812
- Locations
- 🇧🇷
Novartis Investigative Site, São Paulo, SP, Brazil
A Study of Nilotinib Versus Imatinib in GIST Patients
- Conditions
- Gastrointestinal Stromal Tumor (GIST)
- Interventions
- First Posted Date
- 2008-11-05
- Last Posted Date
- 2016-06-16
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 644
- Registration Number
- NCT00785785
- Locations
- 🇻🇪
Novartis Investigative Site, Caracas, Distrito Capital, Venezuela
🇺🇸Birmingham Hematology and Oncology Associates, Birmingham, Alabama, United States
🇺🇸Ocala Oncology Center Dept. of Ocala Oncology Center, Ocala, Florida, United States
Effect of BGG492 on EEG in Patients With Photosensitive Epilepsy
- First Posted Date
- 2008-11-02
- Last Posted Date
- 2016-09-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 13
- Registration Number
- NCT00784212
- Locations
- 🇩🇪
Novartis Investigator Site, Radeberg, Germany
Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia
- First Posted Date
- 2008-10-29
- Last Posted Date
- 2018-11-15
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 116
- Registration Number
- NCT00782067
- Locations
- 🇺🇸
Dana Farber Cancer Institute Hematology / Oncology, Boston, Massachusetts, United States
🇺🇸University of Michigan Comprehensive Cancer Center DeptofMichiganCancerCenter(3), Ann Arbor, Michigan, United States
🇺🇸Georgia Health Sciences University Dept.ofMedicalCollegeOfGeorgia, Augusta, Georgia, United States
Efficacy and Safety of Telbivudine 600mg Tablets in Chinese Patients With Chronic Hepatitis B
- First Posted Date
- 2008-10-28
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2200
- Registration Number
- NCT00781105
- Locations
- 🇨🇳
Novartis Investigative Site, Beijing, China
Efficacy and Safety of Dex-Methylphenidate Extended Release 30 mg Versus 20 mg in Children (6-12 Years) With Attention-Deficit/Hyperactivity Disorder (ADHD) in a Laboratory Classroom Setting.
- Conditions
- Attention-Deficit/Hyperactivity Disorder (ADHD)
- Interventions
- Drug: Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)Drug: Placebo
- First Posted Date
- 2008-10-20
- Last Posted Date
- 2011-06-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 165
- Registration Number
- NCT00776009
- Locations
- 🇺🇸
Claghorn-Lesem Research Clinic, Houston, Texas, United States
🇺🇸Behavioral Neurology, Lubbock, Texas, United States
🇺🇸Clinical Study Center, LLC, Little Rock, Arkansas, United States
Efficacy and Safety of Single Dose of 5 mg Zoledronic Acid in Chinese Patients With Paget's Disease of Bone (PDB)
- First Posted Date
- 2008-10-16
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 9
- Registration Number
- NCT00774020
- Locations
- 🇨🇳
Novartis Investigative Site, Beijing, China
🇨🇳Novartis Investigative site, Shanghai, China